Donna Berry on the Implications of Oral Oncolytics

Donna L. Berry, PhD, RN
Published: Thursday, May 26, 2011

Donna Berry, PhD, RN, AOCN®, FAAN, from the Phyllis F. Cantor Center at the Dana-Farber Cancer Institute on the implications of oral oncolytics as observed in her research on patient adherence to oral oncolytic therapy, symptom management, patient quality of life, and patient decision making in cancer treatment.
Donna Berry, PhD, RN, AOCN®, FAAN, from the Phyllis F. Cantor Center at the Dana-Farber Cancer Institute on the implications of oral oncolytics as observed in her research on patient adherence to oral oncolytic therapy, symptom management, patient quality of life, and patient decision making in cancer treatment.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x